News|Videos|October 22, 2025

Ashland Previews Fall Conference Exhibits, Including Expanded High-Purity Sugar Portfolio: Video Summary

At CPHI and AAPS, Ashland plans to detail the impacts of its advanced excipients: ultra-low nitrite materials curb nitrosamine risk, while high-purity sucrose stabilizes complex biologics.

Ashland is enhancing its pharmaceutical ingredients portfolio, focusing on high-purity excipients for injectables and low-nitrite offerings for oral solid doses, according to an announcement detailing products to be featured at CPHI Frankfurt, from Oct. 28–30, 2025, and AAPS PharmSci 360, to be held in San Antonio, Texas from Nov. 9 to 12, 2025 (1).

Related to this article

October 8th, 2026

CPHI Milan 2026: The Demand for Commercial Spray Drying

Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.

October 7th, 2026

CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care

Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.

October 5th, 2026

CPHI Milan: Why End-to-End Pathway Ownership Matters

Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.

October 16th, 2026

PharmTech Weekly Roundup—October 16, 2026: Rare Diseases, CMC, and AI Accountability

AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.

October 13th, 2026

Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC

Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.

October 9th, 2026

Q&A: Patient-Centric Drug Development Should Start at Product Definition

Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.

October 8th, 2026

CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2

Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.

Trophy and confetti on light background, top view with space for text. Victory concept | Image Credit: ©New Africa -stock.adobe.com

October 6th, 2026

Winners of the 2026 CPHI Pharma Awards Announced

The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.